Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017
Laia Fina A B D , Amy L. Phillips A , Adam T. Jones A , Zoë M. Couzens A , Rachel Drayton C , Daniel Rh. Thomas A and Ananda Giri Shankar AA Public Health Wales, 2 Capital Quarter, Tyndall Street, CF10 4BZ Cardiff, Wales.
B European Program for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Gustav III:s Boulevard 40, 16973 Solna, Stockholm, Sweden.
C Cardiff and Vale University Health Board, Cardiff Royal Infirmary, Glossop Road, CF24 0SZ, Cardiff, Wales.
D Corresponding author. Email: laia.fina@wales.nhs.uk
Sexual Health 16(1) 56-62 https://doi.org/10.1071/SH18091
Submitted: 2 May 2018 Accepted: 16 August 2018 Published: 3 December 2018
Abstract
Background: Pre-exposure prophylaxis (PrEP) was introduced in Sexual Health Services of the Welsh National Health Service (NHS Wales) in July 2017 as a 3-year pilot service. Methods: Data were collected through the pre-existing Sexual Health in Wales Surveillance System, to which codes were added to capture PrEP eligibility, outcome of offer of PrEP, reasons for declining and adherence. Eligibility categories were defined based on nationally agreed criteria: men who have sex with men (MSM) and transgender people at high risk of HIV acquisition; partners of HIV-positive individuals not known to be virally suppressed; and heterosexuals reporting condomless intercourse with a HIV-positive individual not known to be virally suppressed. Results: During the first 6 months, 516 people were eligible, 96% of which were MSM. Overall, 57% of those eligible (296/516) started PrEP. Reasons for declining PrEP were given by 88 (56%) of 157 people; 50 (57%) of whom did not believe themselves to be at risk. Of the available adherence assessments, 89% considered that all risk episodes had been covered. Persistence at 3 months was assessed for 141 people, of which 93 (66%) were still using PrEP. There were no HIV diagnoses in people taking PrEP during the first 6 months. Twenty-nine people were diagnosed with 37 episodes of sexually transmissible infections (STIs) while on PrEP. STI incidence was 105.7 per 100 person-years. Conclusions: The early trend indicates that implementation of PrEP is progressing as planned, and the service has been utilised by clients. This analysis can help refine implementation, inform planning and research around uptake, use and effect in Wales and internationally.
Additional keywords: adherence, antiretrovirals, MSM, PrEP, STIs.
References
[1] Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2017. Geneva: UNAIDS; 2017. Available online at: http://www.unaids.org/en/resources/documents/2017/2017_data_book [verified 10 April 2018].[2] Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, et al Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[3] Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, et al Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367 399–410.
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.Crossref | GoogleScholarGoogle Scholar |
[4] Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, et al Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367 423–34.
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.Crossref | GoogleScholarGoogle Scholar |
[5] Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S, Bangkok Tenofovir Study Group . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381 2083–90.
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.Crossref | GoogleScholarGoogle Scholar |
[6] Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373 2237–46.
| On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.Crossref | GoogleScholarGoogle Scholar |
[7] McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, et al Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387 53–60.
| Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Crossref | GoogleScholarGoogle Scholar |
[8] Welsh Government. Health Secretary, Vaughan Gething, announces all-Wales PrEP trial. Cardiff: Welsh Government; 2017. Available online at: http://gov.wales/newsroom/health-and-social-services/2017/170428trial/?lang=en [verified 24 March 2018].
[9] Public Health Wales. ‘Preparing for PrEP?’ A Review of the Current Evidence for Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection in Wales. Cardiff: Public Health Wales; 2017. Available online at: http://www.wales.nhs.uk/sitesplus/888/opendoc/304708 [verified 24 March 2018].
[10] All Wales Medicines Strategy Group (AWMSG). Emtricitabine/tenofovir disoproxil fumarate (Truvada). Cardiff: AWMSG; 2017. Available online at: http://www.awmsg.org/awmsgonline/app/appraisalinfo/1625 [verified 6 May 2017].
[11] Public Health Wales. Pre-Exposure Prophylaxis (PrEP) Management Guidelines. Cardiff: Public Health Wales NHS Trust; 2017. Available online at: http://www.publichealthnetwork.cymru/files/3814/9458/8248/PrEP_Management_Guidelines_2017_12_05_17.docx [verified 12 May 2017].
[12] Hoornenborg E, Krakower DS, Prins M, Mayer KH. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS 2017; 31 2179–91.
| Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries.Crossref | GoogleScholarGoogle Scholar |
[13] Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS 2016; 11 10–7.
| Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.Crossref | GoogleScholarGoogle Scholar |
[14] Nguyen VK, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, Charest L, Longpré D, Lavoie S, Tossa HG, Thomas R. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS 2018; 32 523–30.
